

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  29D2094484	<b>(X3) Date Survey Completed</b>  08/20/2024
<b>Name of Provider or Supplier</b>  Sweetwater Pain And Spine	<b>Street Address, City, State</b>  10451 Double R Blvd, Reno, NV	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D0000</b>	<p>This Statement of Deficiencies was created as a result of an on-site CLIA recertification survey conducted at your facility on August 20, 2024. The findings and conclusions of any investigation by the Division of Public and Behavioral Health shall not be construed as prohibiting any criminal or civil investigations, actions or other claims for relief that may be available to any party under applicable federal, state, or local laws.</p>
<b>D3027</b>	<p><b>RETENTION REQUIREMENTS</b> CFR(s): 493.1105(a)(1)</p> <p>Test requisitions and authorizations. Retain records of test requisitions and test authorizations, including the patient's chart or medical record if used as the test requisition or authorization, for at least 2 years.</p> <p>This STANDARD is not met as evidenced by: Based on a random review of six patient files, including test requisitions and reports from February 2023 through May 2024, and an interview with the technical consultant, the laboratory failed to retain records of the test requisitions for at least two years. Findings include: 1. A random review of six patients files from February 2023 through May 2024, found that one of six patient files (Sample ID: H3481) indicated that the specimen was collected on May 23, 2024. The test requisition could not be provided by the laboratory. 2. The test results for Sample ID: H3481 were reported on June 6, 2024. 3. These findings were confirmed with the technical consultant on August 20, 2024 at approximately 3:00 PM. The laboratory performs approximately 26,000 toxicology tests annually.</p>
<b>D6021</b>	<p><b>LABORATORY DIRECTOR RESPONSIBILITIES</b> CFR(s): 493.1407(e)(5)</p> <p>The laboratory director is responsible for the overall operation and administration of</p>

the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(5) Ensure that quality assessment programs are established and maintained to assure the quality of laboratory services provided.

This STANDARD is not met as evidenced by:

Based on a review of the laboratory quality assurance (QA) policy, QA records and an interview with the technical consultant, the laboratory director failed to ensure that the QA program was maintained as indicated in the laboratory director approved policy.

Findings include: 1. A review of the laboratory director approved QA policy found that the laboratory director and technical personnel are to complete QA checklists specific to each month. 2. A review of the QA checklists from February 2023 through May 2024 found that the checklists for June 2023, September 2023, December 2023 and January 2024 were not available upon request. 3. These findings were confirmed with the technical consultant on August 20, 2024 at approximately 3:00 PM. The laboratory performs approximately 26,000 toxicology tests annually.